Business context and reporting period
Issuer mismatch: The supplied filing is for resTORbio, Inc., not Adicet Bio, Inc. It is a Form 10-Q for the quarter ended June 30, 2018, filed August 9, 2018. resTORbio was a clinical-stage biotech developing RTB101, alone or with everolimus, for aging-related conditions; it had no product revenue.
Financial performance and position
Amounts below are in millions, except per-share data. The company reported operating losses and no income-tax expense; gross margin is not applicable because it had no product revenue.
| Metric | Q2 2018 | Q2 2017 | Six months 2018 | Six months 2017 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| R&D expense | $11.8 | $3.4 | $20.0 | $6.7 |
| G&A expense | $2.3 | $0.6 | $4.4 | $0.7 |
| Net loss | $13.6 | $4.1 | $23.5 | $7.4 |
| Net loss per share | $0.48 | $0.94 | $0.95 | $2.09 |
| Other income, net | $0.5 | — | $0.9 | — |
At June 30, cash and cash equivalents were $51.4 million and marketable securities were $74.6 million, totaling $125.9 million; current liabilities were $11.6 million and total liabilities $11.6 million. No debt balance is reported. Six-month cash used in operations was $17.1 million; investing cash outflow was $74.8 million, mainly purchases of securities; financing cash inflow was $89.9 million, primarily IPO proceeds. Cash and cash equivalents declined $2.0 million from year-end 2017. Accumulated deficit was $57.2 million.
Changes versus prior comparable periods
- Q2 net loss widened to $13.6 million from $4.1 million, as R&D and G&A expenses rose substantially. Management attributed R&D growth mainly to clinical-trial activity, including the Phase 2b trial.
- For the first half, net loss increased to $23.5 million from $7.4 million. The 2017 comparison included a $3.2 million license-related R&D expense, while 2018 expenses reflected higher clinical-trial spending and increased public-company and personnel costs.
- The January 2018 IPO generated approximately $89.4 million net proceeds. Preferred stock converted into common stock; common shares outstanding were 28,048,315 at June 30.
- Marketable securities rose from none at year-end 2017 to $74.6 million at June 30, principally short-term U.S. Treasury securities. The company recorded $30,000 of unrealized investment losses.
Outlook, commentary, risks and unusual items
- After quarter-end, the company reported Phase 2b top-line results: RTB101 10 mg once daily significantly reduced the percentage of patients with at least one laboratory-confirmed respiratory tract infection versus placebo over 16 weeks. The 10 mg twice-daily and RTB101-everolimus combination cohorts did not meet the primary endpoint. Management planned an end-of-Phase-2 FDA meeting in Q4 2018.
- Management said available cash, cash equivalents and marketable securities were expected to fund operations through 2020, including a pivotal Phase 3 program and an NDA filing assuming successful Phase 3 results. The notes separately state funding should cover at least the next 12 months. These are management estimates dependent on assumptions; the company anticipated significant future expenses and may need additional financing.
- Key uncertainties include clinical efficacy and safety in later-stage trials, regulatory approval, trial enrollment and timing, manufacturing and third-party execution, and the ability to obtain additional capital. No product revenue or profitability was assured.
- The Novartis license carries potential clinical milestones up to $4.3 million, regulatory milestones up to $42 million across two indications, commercial milestones up to $125 million, and tiered royalties. No remaining milestones or royalties were considered achieved or probable at June 30.
- A $0.5 million advance from the Silverstein Foundation, an entity linked to a director, is restricted to research and recorded as a funding advance until qualifying costs are incurred; it is repayable if a positive Phase 3 Parkinson’s trial is achieved.
- No material litigation, material changes in contractual commitments, or off-balance-sheet arrangements were reported. Management judged disclosure controls effective.
Important facts for investors to verify
- Confirm the intended issuer: this filing identifies resTORbio, not Adicet Bio.
- Review complete Phase 2b results and subsequent FDA discussions, including the difference between the once-daily result and the unsuccessful combination and twice-daily cohorts.
- Assess whether the cash runway assumptions and planned Phase 3/NDA work remain achievable given clinical, operating and financing needs.
- Check the Novartis milestone, royalty and license-termination terms and the related-party Silverstein funding agreement.
- Consider continuing losses, rising R&D costs, potential future dilution or financing constraints, and stock-based compensation obligations.